[Morphological compound and indicators of the blood clotting system in severe COVID-19 patients of middle aged and elderly during treatment of Tocilizumab and Thymalin.].
Kuznik. B I BI; Shapovalov. K G KG; Smolyakov. Y N YN; Lukyanov. S A SA; Tereshkov. P P PP; Kazantseva. L S LS; Linkova. N S NS
Key Findings
- Hospital mortality dropped to 20.6% with Thymalin versus 28.4% with Tocilizumab and 40.9% with standard therapy alone.
- Thymalin raised lymphocyte, monocyte, leukocyte and platelet counts, while lowering platelet‑to‑lymphocyte and neutrophil‑to‑lymphocyte ratios.
- Levels of fibrinogen, lactate dehydrogenase and D‑dimer—all linked to clotting risk—were reduced by roughly 20‑80% with Thymalin.
Practical Outcomes
- For biohackers looking to support severe viral illness or improve clotting balance, Thymalin appears more effective than Tocilizumab in this trial. Consider a protocol that adds Thymalin (dose not specified in the abstract) to standard COVID‑19 care, monitoring blood counts and clotting markers. More data on dosing, safety, and availability are needed before widespread adoption.
Summary
In a study of older COVID‑19 patients, adding the peptide Thymalin to standard care cut hospital death rates from about 41% down to 21% and improved blood markers of clotting and immune health better than the drug Tocilizumab.
Abstract
The aim of the work was a comparative study of Tocilizumab and Thymalin effects on the morphological composition and indicators of the blood clotting system in COVID-19 of middle aged and elderly patients. Severe COVID-19 patients were divided into 3 groups: 1st - control (basic therapy), 2nd - basic therapy +Tocilizumab, 3rd - basic therapy +Thymalin. Hospital mortality in COVID-19 patients after standard therapy, Tocilizumab and Thymalin application was 40,9; 28,4 and 20,6% accordingly. The number of platelets increased by 1,5 times, the concentration of fibrinogen in blood decreased by 78% and activated partial thromboplastin time decreased by 9,3% in patients taking Tocilizumab. Under the influence of Tocilizumab, the platelet/white blood cell and platelet/lymphocyte ratios increased by 1,6 and 1,4 times, which may be a predictor of an unfavorable outcome of COVID-19. Thymalin increased the number of lymphocytes and monocytes by 2 times, the number of leukocytes - by 1,3 times, the number of platelets in the blood - by 1,5 times. Thymain decreased the platelet/lymphocyte and neutrophil/lymphocyte ratios by 1,4 times and 2 times. The use of Thymalin decreased the level of fibrinogen, lactate dehydrogenase and D-dimer in the blood by 1,2; 1,8 and 1,7 times, respectively. Thymalin, compared with Tocilizumab, meets the principles of pathogenic therapy for severe COVID-19 of middle aged and elderly patients to a greater extent, having a normalizing effect on the morphological composition and indicators of the blood clotting system.
Study Information
pubmed
2022